123 related articles for article (PubMed ID: 38842354)
1.
Yamatani I; Aono A; Fujiwara K; Asami T; Kamada K; Morishige Y; Igarashi Y; Chikamatsu K; Murase Y; Yamada H; Takaki A; Komiya K; Mitarai S
Microbiol Spectr; 2024 Jul; 12(7):e0008424. PubMed ID: 38842354
[TBL] [Abstract][Full Text] [Related]
2.
Kaushik A; Ammerman NC; Lee J; Martins O; Kreiswirth BN; Lamichhane G; Parrish NM; Nuermberger EL
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642943
[TBL] [Abstract][Full Text] [Related]
3. Dual β-lactam therapy to improve treatment outcome in Mycobacterium abscessus disease.
Pozuelo Torres M; van Ingen J
Clin Microbiol Infect; 2024 Jun; 30(6):738-742. PubMed ID: 38527611
[TBL] [Abstract][Full Text] [Related]
4.
Lomovskaya O; Castanheira M; Lindley J; Rubio-Aparicio D; Nelson K; Tsivkovski R; Sun D; Totrov M; Loutit J; Dudley M
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0044023. PubMed ID: 37800963
[TBL] [Abstract][Full Text] [Related]
5. Strongly Bactericidal All-Oral β-Lactam Combinations for the Treatment of Mycobacterium abscessus Lung Disease.
Negatu DA; Zimmerman MD; Dartois V; Dick T
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0079022. PubMed ID: 36047786
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane β-Lactamase Inhibitor To Augment β-Lactam Action.
Dousa KM; Nguyen DC; Kurz SG; Taracila MA; Bethel CR; Schinabeck W; Kreiswirth BN; Brown ST; Boom WH; Hotchkiss RS; Remy KE; Jacono FJ; Daley CL; Holland SM; Miller AA; Bonomo RA
mBio; 2022 Feb; 13(1):e0352921. PubMed ID: 35073757
[TBL] [Abstract][Full Text] [Related]
7. Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus.
Kaushik A; Gupta C; Fisher S; Story-Roller E; Galanis C; Parrish N; Lamichhane G
Future Microbiol; 2017 May; 12(6):473-480. PubMed ID: 28326811
[TBL] [Abstract][Full Text] [Related]
8. Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection.
Negatu DA; González Del Río R; Cacho-Izquierdo M; Barros-Aguirre D; Lelievre J; Rullas J; Casado P; Ganapathy US; Zimmerman MD; Gengenbacher M; Dartois V; Dick T
Antimicrob Agents Chemother; 2023 Feb; 67(2):e0145922. PubMed ID: 36688684
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against
Dousa KM; Shin E; Kurz SG; Plummer M; Nantongo M; Bethel CR; Taracila MA; Nguyen DC; Kreiswith BN; Daley CL; Remy KE; Holland SM; Bonomo RA
mBio; 2024 Jun; 15(6):e0060924. PubMed ID: 38742824
[TBL] [Abstract][Full Text] [Related]
10.
Chen L; Shashkina E; Kurepina N; Calado Nogueira de Moura V; Daley CL; Kreiswirth BN
Antimicrob Agents Chemother; 2024 May; 68(5):e0017424. PubMed ID: 38557171
[No Abstract] [Full Text] [Related]
11. Select β-Lactam Combinations Exhibit Synergy against
Story-Roller E; Maggioncalda EC; Lamichhane G
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745389
[No Abstract] [Full Text] [Related]
12. Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex
Pandey R; Chen L; Manca C; Jenkins S; Glaser L; Vinnard C; Stone G; Lee J; Mathema B; Nuermberger EL; Bonomo RA; Kreiswirth BN
mBio; 2019 Feb; 10(1):. PubMed ID: 30755518
[TBL] [Abstract][Full Text] [Related]
13. Effect of β-lactamase production and β-lactam instability on MIC testing results for Mycobacterium abscessus.
Rominski A; Schulthess B; Müller DM; Keller PM; Sander P
J Antimicrob Chemother; 2017 Nov; 72(11):3070-3078. PubMed ID: 28961987
[TBL] [Abstract][Full Text] [Related]
14. The
Andersson V; Fröberg G; Dahl VN; Chryssanthou E; Giske C; Schön T; Forsman LD
Int J Mycobacteriol; 2023; 12(3):211-225. PubMed ID: 37721224
[TBL] [Abstract][Full Text] [Related]
15. In vitro effects of diazabicyclooctane β-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex.
Misawa K; Nishimura T; Kashimura S; Enoki Y; Taguchi K; Uno S; Uwamino Y; Matsumoto K; Hasegawa N
Int J Antimicrob Agents; 2022; 60(5-6):106669. PubMed ID: 36064079
[TBL] [Abstract][Full Text] [Related]
16. [In vitro Activity of Rifabutin and Clofazimine to Macrolide-Resistant Mycobacterium abscessus Complex Clinical Isolates].
Sürücüoğlu S; Özkütük N; Gazi H; Çavuşoğlu C
Mikrobiyol Bul; 2023 Oct; 57(4):639-649. PubMed ID: 37885391
[TBL] [Abstract][Full Text] [Related]
17. Minimum Inhibitory Concentrations before and after Antibacterial Treatment in Patients with Mycobacterium abscessus Pulmonary Disease.
Fujiwara K; Uesugi F; Furuuchi K; Tanaka Y; Yoshiyama T; Saotome M; Ohta K; Mitarai S; Morimoto K
Microbiol Spectr; 2021 Dec; 9(3):e0192821. PubMed ID: 34878300
[TBL] [Abstract][Full Text] [Related]
18. Intrinsic Antibacterial Activity of Xeruborbactam
Sun D; Tsivkovski R; Pogliano J; Tsunemoto H; Nelson K; Rubio-Aparicio D; Lomovskaya O
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0087922. PubMed ID: 36102663
[TBL] [Abstract][Full Text] [Related]
19. New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the
Kaushik A; Ammerman NC; Parrish NM; Nuermberger EL
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31209013
[TBL] [Abstract][Full Text] [Related]
20. Mycobacterium abscessus l,d-Transpeptidases Are Susceptible to Inactivation by Carbapenems and Cephalosporins but Not Penicillins.
Kumar P; Chauhan V; Silva JRA; Lameira J; d'Andrea FB; Li SG; Ginell SL; Freundlich JS; Alves CN; Bailey S; Cohen KA; Lamichhane G
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
